Even if you are not currently treating Parkinson’s disease patients, everyone should be aware of the following. Parkinson’s disease is a prototypical disease for the study of all dopamine (catecholamine) related problems. While other dopamine diseases may have some of the problems associated with dopamine management, Parkinson’s disease has them all.
The most effective Parkinson’s treatment is the drug L-dopa, which crosses the blood-brain barrier then is freely metabolized to dopamine without biochemical feedback regulation. 89% of Parkinson’s disease patients take the drug combination L-dopa/carbidopa.
Chronic administration of the drug L-dopa may cause depletion of serotonin and all seven thiols. Speakers at this conference will present peer-reviewed papers documenting how the standard approach of administering L-dopa/carbidopa has been linked to 29 systemic depletions which affect hundreds of enzymes and proteins. Peer-reviewed strategies for depletion identification and management will be presented.